biostudies-literatureUnknown9(16)Wang F<h4>Background</h4>For stage IV non-small cell lung cancer (NSCLC) patients, systemic therapy is the main strategy, and local consolidative therapy tends to be performed for patients with oligometastases. The porpose of this article is to evaluate the prognostic effects of local consolidative therapy for patients with stage IV NSCLC and divide these patients into different subcategories to stratify the prognoses.<h4>Methods</h4>A total of 30,583 patients with stage IV NSCLC were identified in the Surveillance, Epidemiology, and End Results (SEER) database. To identify factors related to high cancer-specific mortality (CSM) rates and compare the prognostic effects of different treatment strategies, a competing risk model was developed. Furthermore, independent prognostic factors identified Annals of translational medicine1293https://www.ebi.ac.uk/biostudies/studies/S-EPMC8422121biostudies-literaturePredicted outcomes of subdividing M1-stage metastatic lung cancer based on the prognosis and the response to local consolidative therapy.PMC8422121Xie DRen YWang FGao JShe YChen CSu HfalsePredicted outcomes of subdividing M1-stage metastatic lung cancer based on the prognosis and the response to local consolidative therapy.<h4>Background</h4>For stage IV non-small cell lung cancer (NSCLC) patients, systemic therapy is the main strategy, and local consolidative therapy tends to be performed for patients with oligometastases. The porpose of this article is to evaluate the prognostic effects of local consolidative therapy for patients with stage IV NSCLC and divide these patients into different subcategories to stratify the prognoses.<h4>Methods</h4>A total of 30,583 patients with stage IV NSCLC were identified in the Surveillance, Epidemiology, and End Results (SEER) database. To identify factors related to high cancer-specific mortality (CSM) rates and compare the prognostic effects of different treatment strategies, a competing risk model was developed. Furthermore, independent prognostic factors identified 2021-01-01T00:00:00Z2021 Aug2025-04-04T09:37:18.636Z2025-04-04T09:37:18.636ZS-EPMC84221213453243010.21037/atm-21-1383